ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Children’s Hospital Los Angeles tests generative AI to translate discharge notes into Spanish

When patients and their families leave the emergency room, they’re usually clutching a sheaf of papers: Called discharge notes, they contain important instructions about how

November 11, 2024

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Responding to the changing clinical landscape of head and neck (H&N) cancer, the American Society for Radiation Oncology (ASTRO) has developed recommendations specific to HPV-positive

June 22, 2024

Tenax raises $100M; Sanofi buys into MeiraGTx

Plus, news about scPharmaceuticals and BiVictriX: Tenax Therapeutics’ $100 million PIPE: The company plans to put the money toward a second … Sign up to

August 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.